腫瘍治療薬の日本市場:化学療法、標的療法、免疫療法、ホルモン療法

◆英語タイトル:Japan Oncology Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy), and Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2019–2026
◆商品コード:AMR9NV118
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2019年8月
◆ページ数:147
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:日本
◆販売価格オプション(消費税別)
Single UserUSD2,580 ⇒換算¥278,640見積依頼/購入/質問フォーム
5 UserUSD3,099 ⇒換算¥334,692見積依頼/購入/質問フォーム
Enterprise UserUSD4,322 ⇒換算¥466,776見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

The Japan oncology drugs market accounted for $9,405 million in 2018, and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026. Cancer is a serious medical condition marked by the presence of tumor cells present in the body. The formation of tumor cells take place when the normal cells grow at an abnormal rate. Moreover, these tumor cells also have the ability to spread to other parts of the body through blood and lymphatic system. In addition, cancer has different stages which are based on the growth pattern of tumor. Therefore, the treatment of cancer differs depending on the stage of cancer. Chemotherapy drugs are mostly employed in the treatment of early stage cancers and similarly targeted therapy and immunotherapy drugs are generally preferred in the treatment of late stage cancers.

Surge in research related to new drug discovery for cancer treatment, rise in incidence of cancer in Japan, and increase in healthcare expenditure boost the growth of Japan oncology drugs market. Moreover, rise in awareness related to early diagnosis of cancer leading to rise in demand of oncology drugs for treatment is another factor that fuels the growth of the market in Japan. Furthermore, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancer such as prostate cancer. In addition, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. Conversely, stringent approval process of oncology drugs in Japan hinders the growth of market.

The Japan oncology drugs market size is studied based on segments, drug class type and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer and others.

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the Japan market
• A qualitative analysis based on innovative products facilitates strategic business planning.

Key Market Segments
By Drug Class Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Hormonal Therapy
By Indication
• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Lung Cancer
• Skin Cancer
• Ovarian Cancer
• Cervical Cancer
• Other Cancers

List of key players profiled in the report:
• Otsuka Holdings Co Ltd
• Johnson and Johnson
• Daiichi Sankyo Co Ltd
• AstraZeneca plc
• AbbVie Inc.
• Celgene Corporation
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Ltd

LIST of OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Sanofi
• Amgen Inc.
• Bayer AG

【レポートの目次】

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies, 2018

3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Rise In Incidence of Cancer
3.4.1.2. Surge In Geriatric Population

3.4.2. Restraint

3.4.2.1. Stringent Approval Process

3.4.3. Opportunity

3.4.3.1. Increase In Number of Pipeline Drugs

3.4.4. Impact Analyses

Chapter 4: Oncology Drugs Market, By Drug Class Type

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Chemotherapy

4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast,

4.3. Targeted Therapy

4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast,

4.4. Immunotherapy

4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast,

4.5. Hormonal Therapy

4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast,

Chapter 5: Oncology Drugs Market, By Indication

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Blood Cancer

5.2.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities
5.2.2. Market Size And Forecast

5.3. Breast Cancer

5.3.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities
5.3.2. Market Size And Forecast

5.4. Gastrointestinal And Urinary Cancer

5.4.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.4.1.1. Market Size And Forecast

5.4.2. Gb/Cholangiocarcinoma

5.4.2.1. Market Size And Forecast

5.4.3. Bladder Cancer

5.4.3.1. Market Size And Forecast

5.4.4. Pancreatic Cancer

5.4.4.1. Market Size And Forecast

5.5. Prostate Cancer

5.5.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.5.1.1. Market Size And Forecast

5.6. Lung Cancer

5.6.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.6.1.1. Market Size And Forecast

5.6.2. Small Cell Lung Cancer

5.6.2.1. Market Size And Forecast

5.7. Skin Cancer

5.7.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.7.1.1. Market Size And Forecast

5.8. Ovarian Cancer

5.8.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.8.1.1. Market Size And Forecast

5.9. Cervical Cancer

5.9.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.9.1.1. Market Size And Forecast

5.10. Kidney Cancer

5.10.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.10.1.1. Market Size And Forecast

5.11. Other Cancers

5.11.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.11.1.1. Market Size And Forecast

Chapter 6: Company Profiles

6.1. Abbvie Inc.

6.1.1. Company Overview
6.1.2. Company Snapshot
6.1.3. Operating Business Segments
6.1.4. Product Portfolio
6.1.5. Business Performance
6.1.6. Key Strategic Moves And Developments: Global

6.2. Astellas Pharma Inc.

6.2.1. Company Overview
6.2.2. Company Snapshot
6.2.3. Operating Business Segments
6.2.4. Product Portfolio
6.2.5. Business Performance
6.2.6. Key Strategic Moves And Developments: Japan
6.2.7. Key Strategic Moves And Developments: Global

6.3. Astrazeneca Plc

6.3.1. Company Overview
6.3.2. Company Snapshot
6.3.3. Operating Business Segments
6.3.4. Product Portfolio
6.3.5. Business Performance
6.3.6. Key Strategic Moves And Developments: Japan
6.3.7. Key Strategic Moves And Developments: Global

6.4. Bristol-Myers Squibb Company

6.4.1. Company Overview
6.4.2. Company Snapshot
6.4.3. Operating Business Segments
6.4.4. Product Portfolio
6.4.5. Business Performance
6.4.6. Key Strategic Moves And Developments: Global

6.5. Celgene Corporation

6.5.1. Company Overview
6.5.2. Company Snapshot
6.5.3. Operating Business Segments
6.5.4. Product Portfolio
6.5.5. Business Performance
6.5.6. Key Strategic Moves And Developments: Global

6.6. Daiichi Sankyo Company, Limited

6.6.1. Company Overview
6.6.2. Company Snapshot
6.6.3. Operating Business Segments
6.6.4. Product Portfolio
6.6.5. Business Performance
6.6.6. Key Strategic Moves And Developments: Japan
6.6.7. Key Strategic Moves And Developments: Global

6.7. Hoffmann-La Roche Ag

6.7.1. Company Overview
6.7.2. Company Snapshot
6.7.3. Operating Business Segments
6.7.4. Product Portfolio
6.7.5. Business Performance
6.7.6. Key Strategic Moves And Developments: Japan
6.7.7. Key Strategic Moves And Developments: Global

6.8. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

6.8.1. Company Overview
6.8.2. Company Snapshot
6.8.3. Operating Business Segments
6.8.4. Product Portfolio
6.8.5. Business Performance
6.8.6. Key Strategic Moves And Developments: Japan
6.8.7. Key Strategic Moves And Developments: Global

6.9. Otsuka Holdings Co., Ltd.

6.9.1. Company Overview
6.9.2. Company Snapshot
6.9.3. Operating Business Segments
6.9.4. Product Portfolio
6.9.5. Business Performance
6.9.6. Key Strategic Moves And Developments: Japan
6.9.7. Key Strategic Moves And Developments: Global

6.10. Takeda Pharmaceutical Company Ltd.

6.10.1. Company Overview
6.10.2. Company Snapshot
6.10.3. Operating Business Segments
6.10.4. Product Portfolio
6.10.5. Business Performance
6.10.6. Key Strategic Moves And Developments: Japan
6.10.7. Key Strategic Moves And Developments: Global

List of Tables

Table 01. Japan Oncology Drugs Market, By Drug Class Type, 2018–2026 ($Million)
Table 02. Japan Oncology Drugs Market, By Indication, 2018–2026 ($Million)
Table 03. Abbvie: Company Snapshot
Table 04. Abbvie: Operating Segments
Table 05. Abbvie: Product Portfolio
Table 06. Astellas: Company Snapshot
Table 07. Astellas: Product Portfolio
Table 08. Astrazeneca: Company Snapshot
Table 09. Astrazeneca: Operating Segments
Table 10. Astrazeneca: Product Portfolio
Table 11. Bristol-Myers Squibb: Company Snapshot
Table 12. Bristol-Myers Squibb: Product Portfolio
Table 13. Celgene: Company Snapshot
Table 14. Celgene: Operating Segments
Table 15. Celgene: Product Portfolio
Table 16. Daiichi-Sankyo: Company Snapshot
Table 17. Daiichi-Sankyo: Operating Segments
Table 18. Daiichi-Sankyo: Product Portfolio
Table 19. Roche: Company Snapshot
Table 20. Roche: Operating Segments
Table 21. Roche: Product Portfolio
Table 22. J&J: Company Snapshot
Table 23. J&J: Operating Segments
Table 24. J&J: Product Portfolio
Table 25. Otsuka: Company Snapshot
Table 26. Otsuka: Operating Segments
Table 27. Otsuka: Product Portfolio
Table 28. Takeda: Company Snapshot
Table 29. Takeda: Product Portfolio

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[腫瘍治療薬の日本市場:化学療法、標的療法、免疫療法、ホルモン療法]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆